Concepedia

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study

B.J. Monk, Prafull Ghatage, Trilok Parekh, Erin D. Henitz, Roland E. Knoblauch, A. Soto Matos-Pita, Antonio Nieto, Y.C. Park, P. S. Cheng., W. Li,

Annals of Oncology · 2015 · 65 citations · 13 references

Concepts

MedicineOncologyPharmacologyChemotherapyGynecologic OncologyMolecular OncologyOncogene MutationsOvarian CancerOvarian Cancer PharmacotherapyOvarian NeoplasiaBrca MutationsBrca1 Mutation RiskDoxorubicin-based TherapyOvarian Cancer ChemotherapyOvarian Cancer Clinical TrialsOvarian Cancer TreatmentTreatment Response BiomarkersTreatment Response Criteria

References

13

Global Cancer Statistics, 2002

Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley et al. · New England Journal of Medicine · 2012 · 1.9K citations

Medicine, Oncology, Pharmacology +14

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Giovanni Germano, Roberta Frapolli, Cristina Belgiovine et al. · Cancer Cell · 2013 · 862 citations · Full text

Life Sciences, Immunology, Oncology +14

Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer

Kelly L. Bolton · JAMA · 2012 · 670 citations · Full text

Medicine, Gynecology, Oncology +17